A series of CeO_(2)@MnO_(2)composites was prepared by deposition-precipitation methods.These materials were used to activate sodium persulfate(PDS)for the oxidation of tetracycline.It is found that the composites,espe...A series of CeO_(2)@MnO_(2)composites was prepared by deposition-precipitation methods.These materials were used to activate sodium persulfate(PDS)for the oxidation of tetracycline.It is found that the composites,especially the CeO_(2)@MnO_(2)-1:4 composites,exhibit better tetracycline removal rates than the pure components.X-ray diffraction(XRD),Raman and scanning electron microscopy(SEM)analyses all indicate that the composite has been successfully prepared with high purity and high crystalline.The XPS analysis shows that the strong interaction between the components promotes the electron transfer.Additionally,the kinetic rate constants of CeO_(2)@MnO_(2)-1:4 after 60 min are 3.8 and 12.7 times higher than pure CeO_(2)and MnO_(2),respectively.CeO_(2)@MnO_(2-)1:4 composite also exhibits excellent catalytic activity for individual and hybrid pollutants.The effects of wastewater matrix,pH,circulation and ion stre ngth on the degradation of tetracycline were investigated.It is found that CeO_(2)@MnO_(2)-1:4 composite has good practical application prospects.CeO_(2)@MnO_(2)composites with synergistic adsorption catalysis can activate PDS and peroxymo no sulfate(PMS)for efficient organic catalytic oxidation.This paper provides the theoretical basis and data support for the practical application of the CeO_(2)@MnO_(2)composite materials.展开更多
As the first-generation tyrosine kinase inhibitor for epidermal growth factor receptor(EGFR-TKI),gefitinib has been proven effective for patients with Del19 or L858R mutations in EGFR.Secondary mutations in EGFR(mainl...As the first-generation tyrosine kinase inhibitor for epidermal growth factor receptor(EGFR-TKI),gefitinib has been proven effective for patients with Del19 or L858R mutations in EGFR.Secondary mutations in EGFR(mainly T790M)confer resistance to gefitinib in~50%of patients.1 However,resistance still occurs in other patients without secondary mutations in EGFR,which indicates that EGFR-independent mechanisms also play a vital role in the gefitinib resistance cascade,which deserves further investigation.展开更多
Metastasis-associated drug resistance accounts for high mortality in ovarian cancer and remains to be a major barrier for effective treatment. In this study, SKOV3/T4, a metastatic subpopulation of ovarian cancer SKOV...Metastasis-associated drug resistance accounts for high mortality in ovarian cancer and remains to be a major barrier for effective treatment. In this study, SKOV3/T4, a metastatic subpopulation of ovarian cancer SKOV3 cells, was enriched to explore potential interventions against metastaticassociated drug resistance. Quantitative genomic and functional analyses were performed and found that slug was significantly increased in the SKOV3/T4 subpopulation and contributed to the high resistance of SKOV3/T4. Further studies showed that slug activated c-Met in a ligand-independent manner due to elevated levels of fibronectin and provoked integrin α V function, which was confirmed by the significant correlation of slug and p-Met levels in 121 ovarian cancer patient samples. Intriguingly,c-Met inhibitor(s) exhibited greatly enhanced anti-cancer effects in slug-positive ovarian cancer models both in vitro and in vivo. Additionally, IHC analyses revealed that slug levels were highly correlated with reduced survival of ovarian cancer patients. Taken together, this study not only uncovers the critical roles of slug in drug resistance in ovarian cancer but also highlights a promising therapeutic strategy by targeting the noncanonical activation of c-Met in slug-positive ovarian cancer patients with poor prognosis.展开更多
基金Project supported by the Science and Technology Project of Henan Province(242102321048,242102321045,232102320211)National Natural Science Foundation of China(22206080)+2 种基金Natural Science Foundation of Jiangsu(SBK2022041070)International Science and Technology Cooperation Projects of Henan Province(232102521009)Natural Science Youth Foundation of Henan Province(232300420336)。
文摘A series of CeO_(2)@MnO_(2)composites was prepared by deposition-precipitation methods.These materials were used to activate sodium persulfate(PDS)for the oxidation of tetracycline.It is found that the composites,especially the CeO_(2)@MnO_(2)-1:4 composites,exhibit better tetracycline removal rates than the pure components.X-ray diffraction(XRD),Raman and scanning electron microscopy(SEM)analyses all indicate that the composite has been successfully prepared with high purity and high crystalline.The XPS analysis shows that the strong interaction between the components promotes the electron transfer.Additionally,the kinetic rate constants of CeO_(2)@MnO_(2)-1:4 after 60 min are 3.8 and 12.7 times higher than pure CeO_(2)and MnO_(2),respectively.CeO_(2)@MnO_(2-)1:4 composite also exhibits excellent catalytic activity for individual and hybrid pollutants.The effects of wastewater matrix,pH,circulation and ion stre ngth on the degradation of tetracycline were investigated.It is found that CeO_(2)@MnO_(2)-1:4 composite has good practical application prospects.CeO_(2)@MnO_(2)composites with synergistic adsorption catalysis can activate PDS and peroxymo no sulfate(PMS)for efficient organic catalytic oxidation.This paper provides the theoretical basis and data support for the practical application of the CeO_(2)@MnO_(2)composite materials.
基金supported by the National Natural Science Foundation of China(No.82102741 to L.Chang)Young Talent Support Project of Henan Province,China(No.2024HYTP042 to L.Chang)+2 种基金Henan Provincial Science and Technology Research Project(China)(No.242102310061 to L.Chang)Shandong Provincial Natural Science Foundation(China)(No.ZR2021QH100 to X.Qi)China Zhongguancun Precision Medicine Science and Technology Foundation(No.ZGC-YXKY-19 to L.Chang).
文摘As the first-generation tyrosine kinase inhibitor for epidermal growth factor receptor(EGFR-TKI),gefitinib has been proven effective for patients with Del19 or L858R mutations in EGFR.Secondary mutations in EGFR(mainly T790M)confer resistance to gefitinib in~50%of patients.1 However,resistance still occurs in other patients without secondary mutations in EGFR,which indicates that EGFR-independent mechanisms also play a vital role in the gefitinib resistance cascade,which deserves further investigation.
基金supported by the National Natural Science Foundation for Distinguished Young Scholar of China (81625024 and 91529304, to Bo Yang)National Natural Science Foundation of China (81673458, to Hong Zhu+2 种基金 81503095, to Xiaoyang Dai)Zhejiang Provincial Natural Science Foundation (LY16H310004, to Xiaoyang Dai China)
文摘Metastasis-associated drug resistance accounts for high mortality in ovarian cancer and remains to be a major barrier for effective treatment. In this study, SKOV3/T4, a metastatic subpopulation of ovarian cancer SKOV3 cells, was enriched to explore potential interventions against metastaticassociated drug resistance. Quantitative genomic and functional analyses were performed and found that slug was significantly increased in the SKOV3/T4 subpopulation and contributed to the high resistance of SKOV3/T4. Further studies showed that slug activated c-Met in a ligand-independent manner due to elevated levels of fibronectin and provoked integrin α V function, which was confirmed by the significant correlation of slug and p-Met levels in 121 ovarian cancer patient samples. Intriguingly,c-Met inhibitor(s) exhibited greatly enhanced anti-cancer effects in slug-positive ovarian cancer models both in vitro and in vivo. Additionally, IHC analyses revealed that slug levels were highly correlated with reduced survival of ovarian cancer patients. Taken together, this study not only uncovers the critical roles of slug in drug resistance in ovarian cancer but also highlights a promising therapeutic strategy by targeting the noncanonical activation of c-Met in slug-positive ovarian cancer patients with poor prognosis.
